Acadia Pharmaceuticals to Participate in TD Cowen's 44th Annual Health Care Conference on March 6, 2024

Group 1 - Acadia Pharmaceuticals will participate in TD Cowen's 44th Annual Health Care Conference on March 6, 2024, at 11:10 a.m. Eastern Time [1] - A live webcast of the presentation will be available on Acadia's website, with an archived recording accessible for approximately one month after the event [1] Group 2 - Acadia Pharmaceuticals has been advancing breakthroughs in neuroscience for 30 years, focusing on vital solutions for patients [2] - The company developed the first and only FDA-approved drug for treating hallucinations and delusions associated with Parkinson's disease psychosis, as well as the first FDA-approved drug for Rett syndrome [2] - Current clinical-stage development efforts are aimed at addressing negative symptoms of schizophrenia, Prader-Willi syndrome, Alzheimer's disease psychosis, and other neuropsychiatric symptoms in central nervous system disorders [2]